Immune Health Supplements Market Growing At 7.4% CAGR Annual Rate To World-wide $29.4 Billion By 2027, According To Fortune™Business Insights; Can B Corp. (OTCQB: CANB) Launches In Conjunction With Dr.Karl Zarse ImmuneX2, Proprietary Super Immune System Supplement Anticipating Shipments In Late November
The immune health supplements market is growing at a quick 7.4% CAGR rate to reach worldwide $29.4 billion by 2027, according to a projection by Fortune™Business Insights. It published an October 2020 report titled, “Immune Health Supplements Market Size, Share & Covid 19 Impact Analysis By Ingredient Type, By Form, By Source Type, By Distribution Channel And Regional Forecast, 2020-2027.” The research firm found that COVID-19 is having a direct impact on driving quicker the market’s growth to a very health-conscious global population. For a sample of the report, contact this web site.
The immune health supplement market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Can B Corp. (OTCQB: CANB), Herbalife Nutrition (NYSE: HLF), Pfizer, Inc. (NYSE: PFE) and Bayer AG (OTC: BAYRY).
In this hot market and billion dollar growth sector, Can B Corp. (OTCQB: CANB), a diversified health and wellness developing company, announced it will begin shipping in November ImmuneX2 a physician-developed proprietary super immune boosting AM/PM supplement. It is designed to optimize the health system of users before needed. Developed in collaboration with Dr. Karl Zarse, ImmuneX2 offers AM/PM dosing for consistent serum concentration. The company anticipates shipping it starting in late November.
“The emergence of COVID-19 has brought the world to a standstill,” the Fortune™ Business Insights report states. It adds, “The COVID-19 pandemic is surging the demand for immune health supplements across the globe. This growth is attributable to the rising reconsideration of health and well being of the masses.” As a result, the report sees distribution rising in pharmacies, drug stores, online stores, specialty stores, supermarkets and other distribution channels. It also sees North America as the single largest market in the future followed by Asia-Pacific. Novel or unique supplements, the report finds, help reinforce competitive edge efforts — as well as a strategy of acquisitions and mergers. In the North American market, the report estimates its size reached $5.89 billion in 2019.
Can B Corp. (OTCQB: CANB) is launching into this fast-growing market in conjunction with Dr. Karl Zarse ImmuneX2, a physician-developed proprietary super immune boosting AM/PM Supplement designed to optimize the health system of users before needed. Shipments are expected to begin In late November, the Company said. Immune Health Supplements Market Growing At 7.4% CAGR Annual Rate To Worldwide $29.4 Billion By 2027, According To Fortune™Business Insights; Can B Corp. (OTCQB: CANB) Launches In Conjunction With Dr.Karl Zarse ImmuneX2, Proprietary Super Immune System Supplement Anticipating Shipments In Late November.
CAN B Corp.’s (OTCQB: CANB) ImmuneX2 Offers Real-Time Education
ImmuneX2, developed in collaboration with Dr. Karl Zarse, offers free member real-time education. The physician-developed immunity optimization formula offers both innate and adaptive immune functionality targeted with a proprietary customer blend focused on immune system optimization. Immune Health Supplements Market Growing At 7.4% CAGR Annual Rate To Worldwide $29.4 Billion By 2027, According To Fortune™Business Insights; Can B Corp. (OTCQB: CANB) Launches In Conjunction With Dr.Karl Zarse ImmuneX2, Proprietary Super Immune System Supplement Anticipating Shipments In Late November.
CAN B Corp.’s (OTCQB: CANB) Sees Doctors and Medical Offices As Prime Candidates
Marco Alfonsi, CAN B Corp.’s (OTCQB: CANB) CEO, said, “We are really excited to have this opportunity to bring to market such a unique, powerful, and needed product such as ImmuneX2. Dr. Zarse states that he and his team have come up with a supercharged proprietary immunity blend. Our fulfillment operations in Lacey, Washington, just outside of Seattle, are ramping up preparation for expected substantial production. Our current and expanding distribution network, especially the medical offices and doctors, are prime candidates to start accepting shipments by the end of November.”
Dr. Karl Zarse’s Credentials
Dr. Karl Zarse is founding member of Idaho Spine And Pain and certified by the American Board of the Interventional Pain Physicians. Refer to website of the Idaho Spine And Pain to learn more.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
